Preemptive pharmacogenetic testing: Insufficient data equal unsatisfactory guidance

Annals of Internal Medicine

Volumn 154, Issue 12, 2011, Pages 842-843

  Mcleod, Howard L ^a   Isaacs, Kim L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBAMAZEPINE; DNA; MERCAPTOPURINE; PROTEIN; RNA; THIOPURINE METHYLTRANSFERASE;

AUTOIMMUNE DISEASE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG DOSE REDUCTION; EDITORIAL; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; GENOTYPE; HUMAN; NEUTROPENIA; PEMPHIGUS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79959628604     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-12-201106210-00016     Document Type: Editorial

References (15)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144-53. [PMID: 21428770]
2. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thio-purines: a systematic review. Ann Intern Med. 2011;154:814-23.
3. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus- implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98. [PMID: 11966406]
4. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet. 1993;341:1151. [PMID: 8097831]
5. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet. 1993;341:436. [PMID: 8094196]
6. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-14. [PMID: 9103127]
7. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-8. [PMID: 9841604]
8. Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med. 1999;38:944-7. [PMID: 10628931]
9. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007; 32:187-95. [PMID: 17381669]
10. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-7. [PMID: 6102739]
11. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 1999;117:527-35. [PMID: 10464128]
12. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al; Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126-33. [PMID: 21428768]
13. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543-6. [PMID: 18855540]
14. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134-43. [PMID: 21428769]
15. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Trans-lational research in cancer genetics: the road less traveled. Public Health Genomics. 2011;14:1-8. [PMID: 20051673]